ArisGlobal LifeSphere Safety is an established enterprise pharmacovigilance platform, and it markets heavily on automation and AI. That matters for this comparison, because it means the conversation is not the familiar 'modern platform versus legacy system' framing — both sides of this evaluation will talk to you about AI-assisted case processing. The differences are elsewhere: in cost profile, in how quickly you can be live, and in who the product is sized for.
How we handle competitor claims on this page
We do not publish feature-by-feature tick tables for other vendors. Safety platforms ship changes continuously and only the vendor can confirm their current capabilities, so a table asserting what a named product does or does not do would be unreliable within months. What follows: factual statements about PVgenix, category-level positioning for the enterprise tier, an honest list of where we are not the right choice, and questions to put to every vendor including us.
Enterprise platforms are not badly built — they are built for a different buyer. These are the signals that you are that different buyer.
- Your case volume does not justify enterprise licensing, and the cost per case is the number your finance team keeps returning to
- You need to be processing cases in weeks, not after a multi-month configuration and qualification programme
- You are a CRO and need to onboard each new sponsor without running a fresh implementation project every time
- You do not have internal IT, DevOps, QA, or CSV capacity to carry an enterprise rollout
- You are buying pharmacovigilance only — not a multi-function platform spanning clinical and regulatory operations
Since automation is central to how enterprise platforms in this tier position themselves, and central to how we position PVgenix, 'we have AI' tells you nothing useful. What separates a defensible implementation from a demo-friendly one is where the human sits and what the audit trail records. Ask these questions of any vendor, including us.
- Which specific steps are AI-assisted — extraction, coding, narrative drafting, literature screening — and which are rules-based rather than inferred?
- Is confidence scored per field, or is there a single confidence value for the whole case? Per-field scoring is what lets you route only the uncertain items to review.
- Can the AI ever set causality, expectedness, or seriousness sign-off? The answer you want is no, structurally, not 'we recommend against configuring it that way'.
- What does the audit trail record about an AI-assisted step — the proposal, the confidence, the reviewer's change, the approver?
- Is straight-through processing scoped to defined low-risk case types, and who controls the thresholds?
- Show me a low-confidence extraction being caught and corrected, on a real screen, in the demo.
For how PVgenix answers each of those, see AI pharmacovigilance software — the short version is that AI proposes and a qualified person decides, enforced structurally rather than by policy.
Factual statements about PVgenix, from our own platform documentation. Put the equivalent questions to the other vendor and compare written answers.
| Dimension | PVgenix |
|---|---|
| Target buyer | CROs, small-to-mid pharma, biotech, generics, and clients buying a complete licence |
| ICSR lifecycle | Intake, triage, data entry, coding, assessment, quality and medical review, and submission on one connected case record |
| AI scope | Extraction from unstructured sources, MedDRA coding proposals, narrative drafting, literature screening — confidence-scored per field with mandatory human review gates |
| AI boundary | Causality, expectedness/listedness, seriousness sign-off, and final case approval can only be set by an authorised user — never by AI |
| Straight-through processing | Configurable, applied only to qualifying low-risk case types, with thresholds set per tenant and case type |
| Regulatory submission | E2B(R2)/E2B(R3), CIOMS I, MedWatch 3500A, regulatory clock and configurable rules engine, ACK reconciliation |
| Gateway | AS2 built into the platform — no separate gateway licence or additional component to qualify |
| Surveillance | Literature monitoring with AI-assisted screening and reviewer confirmation; signal detection using PRR, ROR, BCPNN/IC, EBGM with masking detection |
| Aggregate reporting | DSUR, PBRER/PSUR, PADER with line listings and summary tabulations from one interval query at data lock |
| Deployment | Multi-tenant SaaS or dedicated single-tenant from one codebase; EU, US, and India region hosting options |
| Provisioning | Initial SaaS build about three days plus three days of documentation; new tenants self-provisioned from the portal. IT setup and documentation only — not your qualification |
| Multi-client operation | Tenant isolation, per-tenant configuration and entitlements, per-sponsor compliance reporting |
| Documentation set | VMP, URS, FS, DS, IQ/OQ/PQ, RTM, and SOP templates to support client-led qualification |
| Pricing | Quoted per engagement — contact us |
Validation is environment-specific
PVgenix is validation-ready and audit-ready: it ships with a complete IQ/OQ/PQ documentation package to support client-led validation. 'Validated' is a state achieved only after qualification is executed in a specific client environment.
- You need one vendor across pharmacovigilance, clinical, and regulatory operations — we are a pharmacovigilance platform, not a multi-function suite
- You are a large marketing authorisation holder with a mature estate and deep custom integrations that already work
- Your procurement requires a vendor of a particular size, public-company status, or analyst-report placement
- You want the vendor to run your PV operations or provide regulatory advice — we build and deliver software; PV decisions, regulatory interpretation, and SOP content stay with your qualified personnel
- You need a niche regional submission route or module outside the capability set above; ask us directly, and expect an honest no where that is the answer
Most evaluations get lost in capability matrices when the decision usually turns on two figures: total first-year cost, and time to first live submission. Both are frequently understated in vendor conversations — the first because implementation, qualification support, hosting, and dictionary licences sit outside the headline licence figure, and the second because vendors quote their provisioning time rather than your path to operational go-live.
| Number | Make sure it includes |
|---|---|
| Total first-year cost | Licence, implementation, configuration, qualification support, hosting, gateway (if separate), migration, training, and support tier |
| Time to first live submission | IT provisioning, configuration, data migration, qualification execution, SOP updates, UAT, and training — and which of those the vendor performs versus you |
The decision in one line
If you need an enterprise multi-function suite and have the budget and internal capacity to implement one, stay in that tier. If you are buying pharmacovigilance specifically and the enterprise cost and timeline are the obstacle, a modern cloud-native platform delivers the core ICSR capability — including AI assistance with human control — on a materially lower cost base.
Related reading: Veeva Vault Safety alternatives for the enterprise-cloud comparison, Oracle Argus alternatives for the legacy-enterprise starting point, and pharmacovigilance software cost for where the money actually goes.
Frequently asked questions
Common questions
The landscape splits into legacy enterprise safety systems such as Oracle Argus Safety; other enterprise cloud suites such as Veeva Vault Safety; and modern cloud-native pharmacovigilance platforms such as PVgenix built for CROs and small-to-mid pharma. The right group depends on your case volume, your internal IT and QA capacity, and whether you need a multi-function suite or pharmacovigilance specifically.
Both position on automation, so the differences are in cost profile, provisioning speed, and target buyer. PVgenix covers the full ICSR lifecycle with AI-assisted extraction and coding under mandatory human review gates, E2B(R2)/E2B(R3) submission through a built-in AS2 gateway, literature monitoring, signal detection, aggregate reporting, and QMS — as multi-tenant SaaS or dedicated single-tenant, provisioned in days, priced for CROs and small-to-mid pharma. We are not a multi-function suite spanning clinical and regulatory operations. For current details of any competitor product, confirm with that vendor directly.
Ask where the human sits and what the audit trail records. Specifically: which steps are AI-assisted versus rules-based; whether confidence is scored per field or per case; whether AI can ever set causality, expectedness, or seriousness sign-off; what the audit trail captures about an AI-assisted step; and whether straight-through processing is scoped to defined low-risk case types with client-controlled thresholds. Then ask to see a low-confidence extraction caught and corrected live in the demo.
Not necessarily — cost is largely driven by architecture and hosting model rather than by automation depth. A modern cloud-native platform can carry AI-assisted extraction, coding, and literature screening while running on a more efficient infrastructure footprint than an older architecture requires. What you should check is the boundary: automation that stops short of regulated determinations is a design decision, not a limitation.